Bookmark and Share
BioAssay: AID 504928

Late stage assay provider results from the probe development effort to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): absorbance-based cell-based assay to identify cytotoxic compounds in various cell types

Name: Late stage assay provider results from the probe development effort to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): absorbance-based cell-based assay to identify cytotoxic compounds in various cell types. ..more
_
   
 Tested Compounds
 Tested Compounds
All(1)
 
 
Probe(1)
 
 
Active(1)
 
 
 Tested Substances
 Tested Substances
All(1)
 
 
Probe(1)
 
 
Active(1)
 
 
 Related BioAssays
 Related BioAssays
AID: 504928
Data Source: The Scripps Research Institute Molecular Screening Center (CELL-VIABILITY_INH_MTT_096_Fold-Change-DRUN Round 0 LRH1 IAG)
BioAssay Type: Panel
Depositor Category: NIH Molecular Libraries Probe Production Network, Assay Provider
Deposit Date: 2011-07-07
Hold-until Date: 2012-07-06
Modify Date: 2012-07-11

Data Table ( Complete ):           View Probe Data    View Active Data    View All Data
BioActive Compound: Chemical Probe: 1    Active: 1
Related Experiments
Show more
AIDNameTypeProbeComment
485348Center Based Initiative to identify novel inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based primary assay to identify LRH1 inhibitors (3X%INH)Other depositor-specified cross reference: Primary screen (LRH1 inhibitors in triplicate)
488769Center Based Initiative to identify novel inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): fluorescence-based cell-based quantitative PCR assay to identify inhibitors of LRH-1 target gene expressionOther depositor-specified cross reference: Screen (LRH1 target gene expression inhibitors in triplicate)
488775Center Based Initiative to identify novel inverse agonists of the liver receptor homolog-1 (LRH1; NR5A2): Luminescence-based counterscreen assay to identify inhibitors of the human herpes virus VP16 transcriptional activator protein (VP16)Other depositor-specified cross reference: Counterscreen (VP16 inhibitors in triplicate)
488779Center Based Initiative to identify novel inverse agonists of the liver receptor homolog-1 (LRH1; NR5A2): Luminescence-based counterscreen assay to identify SF-1 inhibitorsOther depositor-specified cross reference: Counterscreen (SF-1 inhibitors in triplicate)
488780Center Based Initiative to identify novel inverse agonists of the liver receptor homolog-1 (LRH1; NR5A2): Luminescence-based dose response counterscreen assay to identify SF1 inhibitorsConfirmatory depositor-specified cross reference: Dose response counterscreen (SF-1 inhibitors in triplicate)
488781Summary of the probe development efforts to identify novel inverse agonists of the liver receptor homolog-1 (LRH1; NR5A2)Summary depositor-specified cross reference: LRH1 IAG Summary
488782Center Based Initiative to identify novel inverse agonists of the liver receptor homolog-1 (LRH1; NR5A2): Luminescence-based dose response assay to identify LRH1 inhibitors (Cyp19 aromatase-luciferase reporter)Confirmatory depositor-specified cross reference: Dose response (LRH1 inhibitors in triplicate)
504933Late stage assay provider results from the probe development effort to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): luminescence-based cell-based assay to identify inhibitors of Star (Steroidogenic acute regulatory protein)Confirmatory2 same project related to Summary assay
504934Late stage assay provider results from the probe development effort to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): luminescence-based high throughput cell-based assay to identify modulators of human nuclear receptorsOther1 same project related to Summary assay
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRISMC)
Center Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Patrick Griffin, TSRI
Network: Molecular Library Probe Production Center Network (MLPCN)
Grant Proposal Number: U54 MH084512
Grant Proposal PI: Patrick Griffin, TSRI
External Assay ID: CELL-VIABILITY_INH_MTT_096_Fold-Change-DRUN Round 0 LRH1 IAG

Name: Late stage assay provider results from the probe development effort to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): absorbance-based cell-based assay to identify cytotoxic compounds in various cell types.

Description:

NR5A2 or Liver receptor homologue-1 (LRH-1) is a member of the NR5A, or Ftz-F1, subfamily V nuclear receptors for which there are four members (1). Murine LRH-1 was originally identified due to its sequence homology to the Drosophila Fushi tarazu factor-1 but orthologs have been subsequently identified in several other species including rat, chicken, horse, zebrafish and human (2-7). LRH-1, and its closest family member steroidogenic factor-1 (SF-1, NR5A1), bind to identical DNA consensus sequences (response elements or REs) and both have the ability to bind phospholipids in their ligand binding domains (LBDs) (8-10). However, LRH-1 and SF-1 are expressed in different tissues and thus are considered likely to have non-overlapping, non-redundant functions. SF-1 expression is confined to steroidogenic tissues and adrenals where it regulates development, differentiation, steroidogenesis and sexual determination (5, 7, 11). LRH-1 is highly expressed in tissues of endodermal origin and its expression is essential for normal liver, intestine, and pancreas function. LRH-1 has also been shown to be expressed in the ovary and adipose tissue (12).

In a very recent report, Chand and colleagues investigated the mechanism of action of LRH-1 in invasive breast cancer cells. They found that LRH-1 promotes motility and cell invasiveness in both ER-positive (MCF-7) and ER-negative (MDA-MB-231) breast cancer cells and similar effects were observed in non-tumorigenic mammary epithelial cells. Interestingly, both remodeling of the actin cytoskeleton and E-cadherin processing were observed when LRH-1 was over-expressed. These findings implicate LRH-1 in promotion of migration and invasion in breast cancer independent of estrogen sensitivity. Together these findings provided strong evidence that LRH-1 plays a significant role in tumor formation both in vitro and in vivo. Therefore, the identification of potent and selective LRH-1 inverse agonists may provide new approaches for the treatment of cancer.

References:

1. Fayard, E., J. Auwerx, and K. Schoonjans, LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends in Cell Biology, 2004. 14(5): p. 250-260.
2. Galarneau, L., J.F. Pare, D. Allard, D. Hamel, L. Levesque, J.D. Tugwood, S. Green, and L. Belanger, The alpha1-fetoprotein locus is activated by a nuclear receptor of the Drosophila FTZ-F1 family. Mol Cell Biol, 1996. 16(7): p. 3853-65.
3. Kudo, T. and S. Sutou, Molecular cloning of chicken FTZ-F1-related orphan receptors. Gene, 1997. 197(1-2): p. 261-8.
4. Boerboom, D., N. Pilon, R. Behdjani, D.W. Silversides, and J. Sirois, Expression and regulation of transcripts encoding two members of the NR5A nuclear receptor subfamily of orphan nuclear receptors, steroidogenic factor-1 and NR5A2, in equine ovarian cells during the ovulatory process. Endocrinology, 2000. 141(12): p. 4647-56.
5. Broadus, J., J.R. McCabe, B. Endrizzi, C.S. Thummel, and C.T. Woodard, The Drosophila beta FTZ-F1 orphan nuclear receptor provides competence for stage-specific responses to the steroid hormone ecdysone. Mol Cell, 1999. 3(2): p. 143-9.
6. Ellinger-Ziegelbauer, H., A.K. Hihi, V. Laudet, H. Keller, W. Wahli, and C. Dreyer, FTZ-F1-related orphan receptors in Xenopus laevis: transcriptional regulators differentially expressed during early embryogenesis. Mol Cell Biol, 1994. 14(4): p. 2786-97.
7. Lavorgna, G., H. Ueda, J. Clos, and C. Wu, FTZ-F1, a steroid hormone receptor-like protein implicated in the activation of fushi tarazu. Science, 1991. 252(5007): p. 848-51.
8. Li, Y., M. Choi, G. Cavey, J. Daugherty, K. Suino, A. Kovach, N.C. Bingham, S.A. Kliewer, and H.E. Xu, Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1. Mol Cell, 2005. 17(4): p. 491-502.
9. Solomon, I.H., J.M. Hager, R. Safi, D.P. McDonnell, M.R. Redinbo, and E.A. Ortlund, Crystal structure of the human LRH-1 DBD-DNA complex reveals Ftz-F1 domain positioning is required for receptor activity. J Mol Biol, 2005. 354(5): p. 1091-102.
10. Krylova, I.N., E.P. Sablin, J. Moore, R.X. Xu, G.M. Waitt, J.A. MacKay, D. Juzumiene, J.M. Bynum, K. Madauss, V. Montana, L. Lebedeva, M. Suzawa, J.D. Williams, S.P. Williams, R.K. Guy, J.W. Thornton, R.J. Fletterick, T.M. Willson, and H.A. Ingraham, Structural Analyses Reveal Phosphatidyl Inositols as Ligands for the NR5 Orphan Receptors SF-1 and LRH-1. Cell, 2005. 120(3): p. 343-355.
11. Luo, X., Y. Ikeda, and K.L. Parker, A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell, 1994. 77(4): p. 481-90.
12. Clyne CD, Speed CJ, Zhou J, Simpson ER, Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes. J Biol Chem. 2002 Jun 7;277(23):20591-7. Epub 2002 Apr 1.

Keywords:

Late stage, late stage AID, assay provider, purchased, synthesized, counterscreen, MTT, ML180, ML179, absorbance, cytotoxicity, viability, survival, growth, proliferation, spectrophotometer, duplicate, dose response, titration, IC50, CC50, nuclear receptor, library, liver receptor homolog 1; liver receptor homolog-1; nuclear receptor NR5A2; nuclear receptor subfamily 5 group A member 2, LRH1, liver, inhibitor, inverse agonist, IAG, transcriptional assay, assay provider, center based initiative, center-based, luciferase, luminescence, selective, Scripps Florida, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN.
Panel Information
Cell Lines
    Data Table(Active)    Data Table(All)Show more
PID§NameSubstancePanel TargetsDescription
ActiveInactive
1Raji Cell Line1
2EuMyc Lymphoma Cell Line1
370Z/3 Cell Line1
49E10 Cell Line1
5Jurkat Cell Line1
6MCF7 Cell Line1
7T47D Cell Line1
8MD-MDA-231 Cell Line1
9HS578 Cell Line1
10SKBR Cell Line1

§ Panel component ID.
Protocol
Assay Overview:
The purpose of this assay is to determine cytotoxicity/viability fold change or cytotoxicity/viability dose response curves for powder samples of possible LRH1 inverse agonist probes candidates, using a variety of tumor cell lines. This assay is based upon the reduction of the yellow tetrazolium salt (MTT) in metabolically active cells to form insoluble purple-blue formazan crystals, which are solubilized by the addition of a detergent. MTT reduction occurs inside cells via the action of mitochondrial dehydrogenases. Formazan production is directly proportional to cell number, and metabolically inactive cells produce low levels of formazan. All values were normalized to DMSO negative control. As designed, a compound that inhibits cell growth or proliferation or is directly cytotoxic, will lead to decreased production of purple formazan crystals, thereby reducing well absorbance. Some compounds were tested in duplicate using a 5-point dilution series starting at a nominal concentration of 10 uM. For some assays, doses tested were 10.0, 3.3, 1.1, 0.37, 0.123, 0.041, 0.0137, and 0.0045 uM. Control treatment was incubation of cells in media alone. Values were normalized to DMSO.
Protocol Summary:
A selection of some of the possible cell types tested in these assays are listed here: Human B lymphocyte (Lymphoma) Raji cells, Mouse B lymphocyte EuMyc Lymphoma cells, Mouse Pre-B lymphocyte (cancer) 70Z/3 cells, 9E10 cells, Mouse T lymphocyte (Leukemia) Jurkat cells, Human Breast Cancer MCF7 cells, Human Breast Cancer T47D cells, Human Breast Cancer MD-MDA-231 cells, Human breast (non-cancer) HS578 cells, Human Breast Cancer SKBR cells. The following describes the culture conditions for each cell line, seeded in 50 ul per well of a 96-well plate (ME indicates mercaptoethanol)
Raji: 1.5x10^4 cells per well, cultured for 2 days in 10%FBS RPMI1640, 2 mM L-Glutamine, Penstrep.
SCR lymphoma ex vivo: 1.5x10^4 cells per well, cultured for 2 days in 10% FBS RPMI1640, 2mM L-Glutamine, Penstrep, 0.5 ng/ml IL7.
ATG7 null lymphoma : 1.5x10^4 cells per well, cultured for 2 days in 10% FBS RPMI1640, 2mM L-Glutamine, Penstrep, 0.5 ng/ml IL7.
U266: 3.0x10^4 cells per well, cultured for 4 days in10% FBS RPMI1640, 2 mM L-Glutamine, Penstrep.
NCI H929: 3.0x10^4 cells per well, cultured for 4 days in 10% FBS RPMI1640, 2 mM L-Glutamine, Penstrep, 5 0nM 2ME.
RPMI8226: 1.5x10^4 cells per well, cultured for 3 days in 10% FBS RPMI1640, 2 mM L-Glutamine, Penstrep.
70Z/3: 1.5x10^4 cells per well, cultured for 3 days in 10% FBS RPMI1640, 2 mM L-Glutamine, Penstrep, 50 nM 2ME.
Jurkat: 3.0x10^4 cells per well, cultured for 3 days in 10% FBS RPMI1640, 2 mM L-Glutamine, Penstrep.
9E10:1.5x10^4 cells per well, cultured for 3 days in 10% FBS RPMI1640, 2 mM L-Glutamine, Penstrep.
MDA231: 0.5x10^4 cells per well, cultured for 3 days in10% FBS DMEM with 25 mM Glucose, 2 mM L-Glutamine, Penstrep.
HS578: 1.0x10^4 cells per well, cultured for 4 days in 10% FBS DMEM with 25 mM Glucose, 2 mM L-Glutamine, Penstrep.
MCF7: 0.5x10^4 cells per well, cultured for 3 days in 10% FBS DMEM with 25 mM Glucose, 2 mM L-Glutamine, Penstrep.
T47D: 0.5x10^4 cells per well, cultured for 3 days in 10% FBS DMEM with 25 mM Glucose, 2 mM L-Glutamine, Penstrep.
SKBR: 1.0x10^4 cells per well, cultured for 4 days in 10% FBS DMEM with 25 mM Glucose, 2 mM L-Glutamine, Penstrep.
PC3: 0.5x10^4 cells per well, cultured for 3 days in 10% FBS RPMI1640, 2 mM L-Glutamine, Penstrep.
Cells were seeded in 96-well plate based on the cell concentrations indicated above, in a volume of 50 ul per well. Cells were cultured in 37 C, 5% CO2 for 3-5 days, as indicated. MTT (Chemicon International) was then added to all well, 10 ul per well, and the cells were allowed to continue culturing for 4 hours. Next was addition of isopropanol/0.04N HCL, 100ul per well, and the well contents were mixed by pipetting up and down to dissolve the formazan into a homogeneous blue solution. Finally, the plates were read at 570 nm and 630 nm. Use dual wavelength of 570 nm subtracted from reference 630 nm.
The percent maximal response (inhibition) for each replicate well of each compound was calculated as follows:
%_Inhibition = Cells_treated_with_Test_Compound / Cells_treated_with_Vehicle_(DMSO)
For selected test compounds, fold inhibition was plotted against compound concentration. Fold change values were calculated from GraphPad Prism software.
PubChem Activity Outcome and Score:
The following applies to each panel in this assay:
Compounds with a fold change value greater than 0.6 were considered inactive. Compounds with a fold change value less than 0.6 were considered active.
Active compounds were given a score of 100 and inactives were given a score of 0.
Raji Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
EuMyc Lymphoma Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
70Z/3 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
9E10 Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
Jurkat Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
MCF7 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
T47D Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
MD-MDA-231 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
HS578 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
SKBR Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
Overall Outcome and Score:
Probe compounds were given a score of 100, actives a score of 50 and inactives a score 0.
The PubChem Activity Score range for active compounds is 100-100. There were no inactive compounds.
List of Reagents:
MTT (Chemicon International)
Comment
This assay was performed by a collaborator of the assay provider. This assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. In this case the results of each separate campaign were assigned "Active/Inactive" status based upon that campaign's specific compound activity cutoff value. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, or compounds that modulate well absorbance. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided.
Categorized Comment - additional comments and annotations
From PubChem:
Assay Format: Cell-based
Assay Cell Type: MDA-MB-231
Result Definitions
Show more
TIDNameDescriptionPID§Panel TargetsHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Outcome [Raji]The BioAssay activity outcome1Outcome
2Score [Raji]The BioAssay activity ranking score1Integer
3Fold Change [1] [Raji] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.1Floatratio
4Fold Change [2] [Raji] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.1Floatratio
5Average Fold Change [Raji] (10μM**)Average of two replicates of normalized fold change at the indicated nominal compound concentration of 10 micromolar.1Floatratio
6Standard Deviation [Raji]Standard deviation of the replicate fold change derived from the normalized fold change of the replicate data for each compound.1Float
7Fold Change, DMSO [1] [Raji]Fold change values of cells treated with DMSO [1]1Floatratio
8Fold Change, DMSO [2] [Raji]Fold change values of cells treated with DMSO [2]1Floatratio
9Average Fold Change, DMSO [Raji]Average fold change value of cells treated with DMSO1Floatratio
10Standard Deviation, DMSO [Raji]Standard deviation of the replicate fold change values of cells treated with DMSO1Float
11Outcome [EuMyc Lymphoma]The BioAssay activity outcome2Outcome
12Score [EuMyc Lymphoma]The BioAssay activity ranking score2Integer
13Fold Change [1] [EuMyc Lymphoma] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.2Floatratio
14Fold Change [2] [EuMyc Lymphoma] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.2Floatratio
15Average Fold Change [EuMyc Lymphoma] (10μM**)Average of two replicates of normalized fold change at the indicated nominal compound concentration of 10 micromolar.2Floatratio
16Standard Deviation [EuMyc Lymphoma]Standard deviation of the replicate fold change derived from the normalized fold change of the replicate data for each compound.2Float
17Fold Change, DMSO [1] [EuMyc Lymphoma]Fold change values of cells treated with DMSO [1]2Floatratio
18Fold Change, DMSO [2] [EuMyc Lymphoma]Fold change values of cells treated with DMSO [2]2Floatratio
19Average Fold Change, DMSO [EuMyc Lymphoma]Average fold change value of cells treated with DMSO2Floatratio
20Standard Deviation, DMSO [EuMyc Lymphoma]Standard deviation of the replicate fold change values of cells treated with DMSO2Float
21Outcome [70Z/3]The BioAssay activity outcome3Outcome
22Score [70Z/3]The BioAssay activity ranking score3Integer
23Fold Change [1] [70Z/3] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.3Floatratio
24Fold Change [2] [70Z/3] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.3Floatratio
25Average Fold Change [70Z/3] (10μM**)Average of two replicates of normalized fold change at the indicated nominal compound concentration of 10 micromolar.3Floatratio
26Standard Deviation [70Z/3]Standard deviation of the replicate fold change derived from the normalized fold change of the replicate data for each compound.3Float
27Fold Change, DMSO [1] [70Z/3]Fold change values of cells treated with DMSO [1]3Floatratio
28Fold Change, DMSO [2] [70Z/3]Fold change values of cells treated with DMSO [2]3Floatratio
29Average Fold Change, DMSO [70Z/3]Average fold change value of cells treated with DMSO3Floatratio
30Standard Deviation, DMSO [70Z/3]Standard deviation of the replicate fold change values of cells treated with DMSO3Float
31Outcome [9E10]The BioAssay activity outcome4Outcome
32Score [9E10]The BioAssay activity ranking score4Integer
33Fold Change [1] [9E10] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.4Floatratio
34Fold Change [2] [9E10] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.4Floatratio
35Average Fold Change [9E10] (10μM**)Average of two replicates of normalized fold change at the indicated nominal compound concentration of 10 micromolar.4Floatratio
36Standard Deviation [9E10]Standard deviation of the replicate fold change derived from the normalized fold change of the replicate data for each compound.4Float
37Fold Change, DMSO [1] [9E10]Fold change values of cells treated with DMSO [1]4Floatratio
38Fold Change, DMSO [2] [9E10]Fold change values of cells treated with DMSO [2]4Floatratio
39Average Fold Change, DMSO [9E10]Average fold change value of cells treated with DMSO4Floatratio
40Standard Deviation, DMSO [9E10]Standard deviation of the replicate fold change values of cells treated with DMSO4Float
41Outcome [Jurkat]The BioAssay activity outcome5Outcome
42Score [Jurkat]The BioAssay activity ranking score5Integer
43Fold Change [1] [Jurkat] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.5Floatratio
44Fold Change [2] [Jurkat] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.5Floatratio
45Average Fold Change [Jurkat] (10μM**)Average of two replicates of normalized fold change at the indicated nominal compound concentration of 10 micromolar.5Floatratio
46Standard Deviation [Jurkat]Standard deviation of the replicate fold change derived from the normalized fold change of the replicate data for each compound.5Float
47Fold Change, DMSO [1] [Jurkat]Fold change values of cells treated with DMSO [1]5Floatratio
48Fold Change, DMSO [2] [Jurkat]Fold change values of cells treated with DMSO [2]5Floatratio
49Average Fold Change, DMSO [Jurkat]Average fold change value of cells treated with DMSO5Floatratio
50Standard Deviation, DMSO [Jurkat]Standard deviation of the replicate fold change values of cells treated with DMSO5Float
51Outcome [MCF7]The BioAssay activity outcome6Outcome
52Score [MCF7]The BioAssay activity ranking score6Integer
53Fold Change [1] [MCF7] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.6Floatratio
54Fold Change [2] [MCF7] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.6Floatratio
55Average Fold Change [MCF7] (10μM**)Average of two replicates of normalized fold change at the indicated nominal compound concentration of 10 micromolar.6Floatratio
56Standard Deviation [MCF7]Standard deviation of the replicate fold change derived from the normalized fold change of the replicate data for each compound.6Float
57Fold Change, DMSO [1] [MCF7]Fold change values of cells treated with DMSO [1]6Floatratio
58Fold Change, DMSO [2] [MCF7]Fold change values of cells treated with DMSO [2]6Floatratio
59Average Fold Change, DMSO [MCF7]Average fold change value of cells treated with DMSO6Floatratio
60Standard Deviation, DMSO [MCF7]Standard deviation of the replicate fold change values of cells treated with DMSO6Float
61Outcome [T47D]The BioAssay activity outcome7Outcome
62Score [T47D]The BioAssay activity ranking score7Integer
63Fold Change [1] [T47D] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.7Floatratio
64Fold Change [2] [T47D] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.7Floatratio
65Average Fold Change [T47D] (10μM**)Average of two replicates of normalized fold change at the indicated nominal compound concentration of 10 micromolar.7Floatratio
66Standard Deviation [T47D]Standard deviation of the replicate fold change derived from the normalized fold change of the replicate data for each compound.7Float
67Fold Change, DMSO [1] [T47D]Fold change values of cells treated with DMSO [1]7Floatratio
68Fold Change, DMSO [2] [T47D]Fold change values of cells treated with DMSO [2]7Floatratio
69Average Fold Change, DMSO [T47D]Average fold change value of cells treated with DMSO7Floatratio
70Standard Deviation, DMSO [T47D]Standard deviation of the replicate fold change values of cells treated with DMSO7Float
71Outcome [MD-MDA-231]The BioAssay activity outcome8Outcome
72Score [MD-MDA-231]The BioAssay activity ranking score8Integer
73Fold Change [1] [MD-MDA-231] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.8Floatratio
74Fold Change [2] [MD-MDA-231] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.8Floatratio
75Average Fold Change [MD-MDA-231] (10μM**)Average of two replicates of normalized fold change at the indicated nominal compound concentration of 10 micromolar.8Floatratio
76Standard Deviation [MD-MDA-231]Standard deviation of the replicate fold change derived from the normalized fold change of the replicate data for each compound.8Float
77Fold Change, DMSO [1] [MD-MDA-231]Fold change values of cells treated with DMSO [1]8Floatratio
78Fold Change, DMSO [2] [MD-MDA-231]Fold change values of cells treated with DMSO [2]8Floatratio
79Average Fold Change, DMSO [MD-MDA-231]Average fold change value of cells treated with DMSO8Floatratio
80Standard Deviation, DMSO [MD-MDA-231]Standard deviation of the replicate fold change values of cells treated with DMSO8Float
81Outcome [HS578]The BioAssay activity outcome9Outcome
82Score [HS578]The BioAssay activity ranking score9Integer
83Fold Change [1] [HS578] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.9Floatratio
84Fold Change [2] [HS578] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.9Floatratio
85Average Fold Change [HS578] (10μM**)Average of two replicates of normalized fold change at the indicated nominal compound concentration of 10 micromolar.9Floatratio
86Standard Deviation [HS578]Standard deviation of the replicate fold change derived from the normalized fold change of the replicate data for each compound.9Float
87Fold Change, DMSO [1] [HS578]Fold change values of cells treated with DMSO [1]9Floatratio
88Fold Change, DMSO [2] [HS578]Fold change values of cells treated with DMSO [2]9Floatratio
89Average Fold Change, DMSO [HS578]Average fold change value of cells treated with DMSO9Floatratio
90Standard Deviation, DMSO [HS578]Standard deviation of the replicate fold change values of cells treated with DMSO9Float
91Outcome [SKBR]The BioAssay activity outcome10Outcome
92Score [SKBR]The BioAssay activity ranking score10Integer
93Fold Change [1] [SKBR] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.10Floatratio
94Fold Change [2] [SKBR] (10μM**)Indicates normalized fold change at the indicated nominal compound concentration of 10 micromolar.10Floatratio
95Average Fold Change [SKBR] (10μM**)Average of two replicates of normalized fold change at the indicated nominal compound concentration of 10 micromolar.10Floatratio
96Standard Deviation [SKBR]Standard deviation of the replicate fold change derived from the normalized fold change of the replicate data for each compound.10Float
97Fold Change, DMSO [1] [SKBR]Fold change values of cells treated with DMSO [1]10Floatratio
98Fold Change, DMSO [2] [SKBR]Fold change values of cells treated with DMSO [2]10Floatratio
99Average Fold Change, DMSO [SKBR]Average fold change value of cells treated with DMSO10Floatratio
100Standard Deviation, DMSO [SKBR]Standard deviation of the replicate fold change values of cells treated with DMSO10Float

** Test Concentration. § Panel component ID.
Additional Information
Grant Number: U54 MH084512

PageFrom: